Department of Clinical Pathology, National Cancer Institute Cairo University, Cairo, Egypt.
Department of Medical Oncology, National Cancer Institute Cairo University, Cairo, Egypt.
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241292665. doi: 10.1177/03946320241292665.
We aimed to evaluate the expression profiles of five circulating lncRNAs (HOTAIR, MALAT-1, XIST, SNHG15, and H19) in DLBCL patients and explore potential associations between their expression and different clinicopathological features. Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma (NHL), exhibits marked genetic and clinical heterogeneity, emphasizing the need for improved tools for risk stratification. Long non-coding RNAs (lncRNAs) emerged as regulators in different cellular processes and have been linked to cancer pathogenesis. Real-time quantitative PCR (qRT-PCR) was used to evaluate lncRNA expression in the plasma of 65 newly diagnosed adult DLBCL patients and 30 age-matched controls. HOTAIR expression was significantly elevated in DLBCL patients, while SNHG15 was significantly downregulated. Interestingly, both HOTAIR and SNHG15 demonstrated robust discriminatory power between DLBCL and healthy individuals, achieving area under the curve (AUC) values of 69% and 71%, respectively. H19 expression displayed a significant association with early-stage (stage I) DLBCL. While upregulated HOTAIR was a significant independent predictor of poor prognosis, high SNHG15 expression appeared to have a protective effect on mortality rates. Our findings suggest that circulating lncRNA expression patterns are promising tools as non-invasive biomarkers for diagnosis of DLBCL. Specific lncRNAs, such as HOTAIR, SNHG15, and H19, could offer potential for disease staging and patient prognosis. Long-term follow-up studies are recommended to further elucidate the interplay between these lncRNAs and survival rates, as well as their interactions with other genetic and pathological features of DLBCL.
我们旨在评估五种循环长非编码 RNA（HOTAIR、MALAT-1、XIST、SNHG15 和 H19）在弥漫性大 B 细胞淋巴瘤（DLBCL）患者中的表达谱，并探讨其表达与不同临床病理特征之间的潜在关联。弥漫性大 B 细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤（NHL），表现出显著的遗传和临床异质性，强调需要改进风险分层工具。长非编码 RNA（lncRNA）作为不同细胞过程的调节剂出现，并与癌症发病机制有关。实时定量 PCR（qRT-PCR）用于评估 65 例新诊断的成人 DLBCL 患者和 30 名年龄匹配对照者血浆中的 lncRNA 表达。HOTAIR 在 DLBCL 患者中表达显著升高，而 SNHG15 表达显著下调。有趣的是，HOTAIR 和 SNHG15 均在 DLBCL 患者与健康个体之间具有强大的区分能力，AUC 值分别为 69%和 71%。H19 的表达与早期（I 期）DLBCL 显著相关。上调的 HOTAIR 是预后不良的独立显著预测因子，而高表达的 SNHG15 似乎对死亡率有保护作用。我们的研究结果表明，循环 lncRNA 表达模式是作为 DLBCL 非侵入性诊断生物标志物的有前途的工具。特定的 lncRNA，如 HOTAIR、SNHG15 和 H19，可能为疾病分期和患者预后提供潜在价值。建议进行长期随访研究，以进一步阐明这些 lncRNA 与生存率之间的相互作用，以及它们与 DLBCL 的其他遗传和病理特征之间的相互作用。
